Bridgebio Pharma Inc (BBIO)
$27.05
+0.35
(+1.31%)▲
Performance
- $26.62$27.79$27.05
1.59%
Downside
Day's Volatility :4.21%
Upside
2.66%
- $21.62$44.32$27.05
20.07%
Downside
52 Weeks Volatility :51.22%
Upside
38.97%
Returns
| Period | Bridgebio Pharma Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 7.32% | 6.5% | 0.0% |
6 Months | -25.71% | 7.1% | 0.0% |
1 Year | -17.62% | 9.8% | 0.0% |
3 Years | -52.58% | 14.2% | -20.2% |
Highlights
Market Capitalization | 4.9B |
Book Value | - $5.61 |
Earnings Per Share (EPS) | -3.23 |
Wall Street Target Price | 49.75 |
Profit Margin | -246.24% |
Operating Margin TTM | 1.77% |
Return On Assets TTM | -40.08% |
Return On Equity TTM | -1789.67% |
Revenue TTM | 218.6M |
Revenue Per Share TTM | 1.29 |
Quarterly Revenue Growth YOY | 11461.9% |
Gross Profit TTM | 74.2M |
EBITDA | -466.4M |
Diluted Eps TTM | -3.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.56 |
EPS Estimate Next Year | -2.93 |
EPS Estimate Current Quarter | -0.89 |
EPS Estimate Next Quarter | -0.93 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 83.92%
Technicals Summary
Sell
Neutral
Buy
Bridgebio Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Bridgebio Pharma Inc | 13.33% | -25.71% | -17.62% | -52.58% | -5.89% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Bridgebio Pharma Inc | NA | NA | NA | -2.56 | -17.9 | -0.4 | NA | -5.61 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Bridgebio Pharma Inc | Buy | $4.9B | -5.89% | NA | -246.24% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Bridgebio Pharma Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 1.74M → 211.12M (in $), with an average increase of 99.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -176.99M → -35.21M (in $), with an average increase of 191.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 79.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 239.1%
Institutional Holdings
Kohlberg Kravis Roberts & Co LP
16.60%Viking Global Investors LP
13.42%Vanguard Group Inc
7.07%BlackRock Inc
5.59%Aisling Capital Management LP
3.24%State Street Corporation
2.88%
Corporate Announcements
Bridgebio Pharma Inc Earnings
Bridgebio Pharma Inc’s price-to-earnings ratio stands at None
Read More
Company Information
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Organization | Bridgebio Pharma Inc |
Employees | 550 |
CEO | Dr. Neil Kumar Ph.D. |
Industry | Health Technology |
